MCL
PRME icon

MWG Caph Ltd’s Prime Medicine PRME Stock Holding History

MWG Caph Ltd’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.22M Buy
+1,792,210
New +$7.97M 8.59% 3

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

MWG Caph Ltd's PRME Position: Q4 2025 in Review

MWG Caph Ltd opened a new position in Prime Medicine (PRME) in Q4 2025: 1,792,210 shares worth $6.22M. The stake represents 8.59% of the portfolio and ranks #3 among its holdings.

183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • MWG Caph Ltd held 1,792,210 shares of Prime Medicine worth $6.22M as of Q4 2025.
  • Prime Medicine was a new MWG Caph Ltd position in Q4 2025.
  • Prime Medicine made up 8.59% of MWG Caph Ltd's portfolio in Q4 2025, its #3 holding.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on MWG Caph Ltd's 13F filing for Q4 2025, filed 17 Feb 2026.